Tsapis M.,Jean Verdier University Hospital |
Tsapis M.,Avicenne University Hospital |
Chabane H.,Delafontaine Hospital |
Teychene A.M.,Jean Verdier University Hospital |
And 3 more authors.
Revue Francaise d'Allergologie | Year: 2013
Allergic reactions following snail ingestion in house dust mite-sensitized patients are well known, although the allergens concerned in the cross-reactivity remain to be identified. We report the case of a fatal anaphylactic reaction following snail ingestion in a 10-year old boy, which occurred 2. months after conclusion of 3. years of house dust mite subcutaneous immunotherapy. This case highlights a possible cross-reaction between food and inhalant allergens leading to a fatal outcome. We discuss the relation between house dust mite immunotherapy and this fatal food allergic reaction. Conclusion: Physicians should be aware of the possibility of severe anaphylaxis following snail ingestion in house dust mite allergic patients undergoing subcutaneous immunotherapy as this appears to constitute a risk factor for such reactions. © 2013 Elsevier Masson SAS. Source
Hoxha M.,Allergology |
Deliu A.,University of Tirana |
Nikolla E.,University of Tirana |
Loloci G.,University of Tirana |
Kalo T.,University of Tirana
Macedonian Journal of Medical Sciences | Year: 2014
Food-dependent exercise-induced anaphylaxis (FDEIA), is a severe form of allergy for which the ingestion of a specific food, usually before physical exercise induces symptoms of anaphylaxis. Patients typically have IgE antibodies to the food that triggers the reactions; however, the symptoms appear only if the co-factors act together. The most common reported cause of these reactions seems to be wheat. In some cases FDEIA is displayed even when the food is eaten immediately after exercise, showing that in FDEIA, not the sequence but rather the coincidence of triggering factors use, is of crucial importance. The risk to develop anaphylaxis in these patients depends on the presence and, in some cases, on the amount of cofactors of anaphylaxis. There are lots of evidences about the role of NSAIDs as cofactors of anaphylaxis. © 2014 Hoxha et al. Source
Acta Biomedica | Year: 2015
Background: Seasonal Allergic rhinitis (SAR) is characterized by runny nose, congestion, sneezing and sinus pressure. A clinical study was performed to demonstrate the efficacy of Lertal®, an innovative food supplement containing Quercetin, Perilla frutescens and Vitamin D3 formulated in a double layer “fast-slow” release tablet form, in the relief of symptoms of seasonal allergic rhinitis and in the reduction of consumption of anti-allergic drugs. Patients and methods: 23 subjects enrolled in the open clinical study had at least one year history of allergic rhinitis and positive skin prick test or RAST to Parietaria officinalis pollen. At baseline, the subjects had symptoms of nasal and/or ocular seasonal allergic rhinitis. The activity of the food supplement was evaluated using the Total Symptoms Score at first (baseline) and second (final) visit, after one month of supplementation. The consumption of anti-allergic drugs was also evaluated. Results: All subjects enrolled completed the study. The comparison of the scores obtained in the two visits (baseline and final) showed a highly significant reduction of the overall symptoms: approximately 70% for symptom scores and 73% in use of anti-allergic drugs. Sneezing, rhinorrhea, nasal obstruction, ocular itching, lacrimation and congestion of the conjunctiva, all showed a highly significant reduction. No noteworthy side effect was recorded and all patients finished the study with good compliance. Conclusions: The results showed a clear efficacy of the food supplement Lertal® in reducing nasal and/or eye symptoms. This activity was objectively confirmed by the reduction in the consumption of anti-allergic drugs used to relieve symptoms. © Mattioli 1885. Source
Spielmanns M.,St Remigius Hospital |
Spielmanns M.,Witten/Herdecke University |
Fuchs-Bergsma C.,St Remigius Hospital |
Winkler A.,St Remigius Hospital |
And 3 more authors.
Respiratory Care | Year: 2015
BACKGROUND: It is well established that physical training enhances functionality and quality of life in patients with COPD. However, little data exist concerning the effects of the usefulness of oxygen supply during exercise training for > 3 months in patients with COPD who are normoxemic at rest and during exercise. We hypothesized that oxygen supply during training sessions enables higher training intensity and thus optimizes training results in patients with COPD. METHODS: In this blinded randomized controlled study, we carried out a 24-week training program with progressively increasing loads involving large muscle groups. In addition, we compared the influences of oxygen supplementation. Thirty-six subjects with moderate-to-severe COPD who were not dependent on long-term oxygen therapy trained under supervision for 24 weeks (3 times/week at 30 min/session). Subjects were randomized into 2 groups: oxygen supply via nasal cannula at a flow of 4 L/min and compressed air at the same flow throughout the training program. Lung function tests at rest (inspiratory vital capacity, FEV1, Tiffeneau index), cycle spiroergometry (peak ventilation, peak oxygen uptake, peak respiratory exchange rate, submaximal and peak lactic acid concentrations), 6-min walk tests, and quality-of-life assessments (Medical Outcomes Study 36-Item Short Form questionnaire) were conducted before and after 12 and 24 weeks. RESULTS: Independent of oxygen supplementation, statistically significant improvements occurred in quality of life, maximal tolerated load during cycling, peak oxygen uptake, and 6-min walk test after 12 weeks of training. Notably, there were no further improvements from 12 to 24 weeks despite progressively increased training loads. CONCLUSIONS: Endurance training 3 times/week resulted in significant improvements in quality of life and exercise capacity in subjects with moderate-to-severe COPD within the initial 12 weeks, followed by a stable period over the following 12 weeks with no further benefits of supplemental oxygen. © 2015 Daedalus Enterprises. Source
Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the "Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group"
Scarsi M.,University of Brescia |
Radice A.,Microbiology and Virology Institute |
Pregnolato F.,Allergology |
Ramoni V.,Internal Medicine Unit |
And 16 more authors.
Clinical and Experimental Rheumatology | Year: 2014
Objective To verify the association between the presence of specific anti-52 Ro/SSA-p200 antibodies and congenital heart block (CHB). Methods 207 pregnant Italian women carrying anti-Ro/SSA Ab were retrospectively evaluated. Anti-p200 Ab were investigated in the mothers' sera by ELISA (Euro-Diagnostica,Wieslab SS-A p200). Results CHB occurred in 42 children (34 complete CHB), whereas 165 were not affected. All CHB cases were previously identified with an ELISA screening for anti-Ro/SSA 60 kD Ab. Anti-p200 Ab were more frequently positive (81.0% vs. 59.1%, p=0.013) and at a higher titer in CHB mothers (Absorbance ratio: 2.030 (0.208-4.052) vs. 0.925 (0.200-3.816); p=0.017). This association was maintained even when the 42 mothers of children with CHB were compared with a control group matched for age and diagnosis (80.9% vs. 50.0%; p=0.006). The presence of anti-p200 Ab provided an odds ratio (OR) for CHB of 2.98 (CI: 1.30-6.83), which was higher than that of other variables, such as maternal disease and other antibody specificities. CHB risk significantly decreased in the absence of this fine specificity (OR:0.34, CI: 0.15-0.77). However, while the negative predictive value related to anti-Ro/SSA 60 kD Ab ELISA was 100%, almost 20% of mothers negative for anti-p200 Ab delivered babies with CHB. Conclusion Anti-p200 antibodies seem to be associated with CHB with a higher probability than anti-Ro/SSA Ab, and therefore may be an additional test to identify mothers at higher risk to deliver affected children. An ELISA screening for anti-Ro/SSA 60 kD Ab is nevertheless mandatory given the probability of developing CHB also in the absence of anti-p200 Ab. © Clinical and Experimental Rheumatology 2014. Source